Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
8.39
-0.58 (-6.47%)
Oct 13, 2026, 4:00 PM EDT - Market closed
Sight Sciences Revenue
Sight Sciences had revenue of $23.39M in the quarter ending June 30, 2026, with 19.55% growth. This brings the company's revenue in the last twelve months to $83.38M, up 9.27% year-over-year. In the year 2025, Sight Sciences had annual revenue of $77.36M, down -3.13%. That makes Sight Sciences the 24,039th largest company in the world by revenue and 3,421st in the United States.
Revenue (ttm)
$83.38M
Revenue Growth
+9.27%
P/S Ratio
5.54
Revenue / Employee
$448,263
Employees
186
Market Cap
462.19M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77.36M | -2.50M | -3.13% |
| Dec 31, 2024 | 79.87M | -1.19M | -1.47% |
| Dec 31, 2023 | 81.06M | 9.73M | 13.63% |
| Dec 31, 2022 | 71.33M | 22.38M | 45.70% |
| Dec 31, 2021 | 48.96M | 21.32M | 77.12% |
| Dec 31, 2020 | 27.64M | 4.29M | 18.38% |
| Dec 31, 2019 | 23.35M | 15.82M | 210.07% |
| Dec 31, 2018 | 7.53M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tactile Systems Technology | 350.31M |
| OrthoPediatrics | 252.72M |
| Cerus | 221.55M |
| NeuroPace | 106.99M |
| Delcath Systems | 95.42M |
| AVITA Medical | 75.63M |
| 908 Devices | 60.84M |
| BrainsWay | 60.70M |
SGHT News
- 8 days ago - Citi ups Sight Sciences target, opens ‘upside 90-day catalyst watch’ - TheFly
- 12 days ago - Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Sight Sciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15 - GlobeNewsWire
- 7 weeks ago - Sight Sciences announces updated TearCare System Indications for Use - TheFly
- 7 weeks ago - TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease - GlobeNewsWire
- 1 month ago - Sight Sciences price target raised to $8 from $6 at Citi - TheFly
- 2 months ago - Sight Sciences price target raised to $8 from $7 at UBS - TheFly